Monika E Hegi

List of Publications by Year in Descending Order

141 papers	28,129 citations	68 h-index	167 g-index
168 ext. papers	33,326 ext. citations	8.8 avg, IF	6.58 L-index

#	Paper	IF	Citations
141	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. *Acta Neuropathologica Communications*, **2022**, 10, 39	7.3	1
140	Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis.. *Nature Cancer*, **2021**, 2, 1086-1101	15.4	6
139	Hyperpolarized C-glucose magnetic resonance highlights reduced aerobic glycolysis in vivo in infiltrative glioblastoma. *Scientific Reports*, **2021**, 11, 5771	4.9	4
138	BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. *Neuro-Oncology*, **2021**, 23, 1680-1692	1	5
137	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature Reviews Clinical Oncology*, **2021**, 18, 170-186	19.4	204
136	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. *Neuro-Oncology Advances*, **2021**, 3, vdab035	0.9	0
135	Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice. *Acta Neuropathologica Communications*, **2021**, 9, 133	7.3	1
134	An integrated pipeline for comprehensive analysis of immune cells in human brain tumor clinical samples. *Nature Protocols*, **2021**, 16, 4692-4721	18.8	2
133	Diagnostic Surveillance of High-Grade Gliomas: Towards Automated Change Detection Using Radiology Report Classification. *Communications in Computer and Information Science*, **2021**, 423-436	0.3	
132	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. *Cell*, **2020**, 181, 1643-1660.e17	56.2	200
131	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro-Oncology*, **2020**, 22, 1073-1113	1	178
130	CBIO-13. EPIGENETIC DEREGULATION OF NUCLEAR TRANSLOCATION - A NOVEL MECHANISM FOR TREATMENT RESISTANCE IN GLIOBLASTOMA. *Neuro-Oncology*, **2020**, 22, ii18-ii18	1	
129	COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. *Neuro-Oncology*, **2020**, 22, ii27-ii27	1	
128	The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. *Drug Resistance Updates*, **2019**, 43, 29-37	23.2	19
127	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. *Molecular Cancer Therapeutics*, **2019**, 18, 1565-1576	6.1	6
126	Improving survival in molecularly selected glioblastoma. *Lancet, The*, **2019**, 393, 615-617	40	20
125	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. *Neuro-Oncology*, **2019**, 21, 167-178	1	92

124	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. *Clinical Cancer Research*, **2019**, 25, 1809-1816	12.9	59
123	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162
122	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. *Acta Neuropathologica*, **2018**, 135, 601-615	14.3	54
121	In vivo characterization of brain metabolism by H MRS, C MRS and FDG PET reveals significant glucose oxidation of invasively growing glioma cells. *International Journal of Cancer*, **2018**, 143, 127-138	7.5	12
120	Toward methylation-based classification of central nervous system tumors. *Neuro-Oncology*, **2018**, 20, 579-581	1	1
119	Glioma epigenetics: From subclassification to novel treatment options. *Seminars in Cancer Biology*, **2018**, 51, 50-58	12.7	197
118	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncology, The*, **2017**, 18, e315-e329	21.7	599
117	Correlation of immune phenotype with IDH mutation in diffuse glioma. *Neuro-Oncology*, **2017**, 19, 1460-1468	7.1	144
116	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. *Neuro-Oncology*, **2017**, 19, 1119-1126	1	82
115	Evidence-based management of adult patients with diffuse glioma - AuthorsRreply. *Lancet Oncology, The*, **2017**, 18, e430-e431	21.7	4
114	Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?. *Neuro-Oncology Practice*, **2017**, 4, 241-247	2.2	11
113	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 318, 2306-2316	27.4	875
112	Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity. *Oncotarget*, **2017**, 8, 110490-110502	3.3	18
111	WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. *Oncogene*, **2016**, 35, 12-21	9.2	101
110	Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T. *NMR in Biomedicine*, **2016**, 29, 1577-1589	4.4	7
109	Reply to F. Felix et al and M.F. Fay et al. *Journal of Clinical Oncology*, **2016**, 34, 3107-8	2.2	1
108	LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2016**, 18, i1-i1	1	14
107	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. *Journal of Clinical Oncology*, **2016**, 34, 731-9	2.2	108

106	Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. *Journal of Molecular Diagnostics*, **2016**, 18, 350-361	5.1	54
105	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget*, **2016**, 7, 15018-32	3.3	49
104	Current management of low-grade gliomas. *Current Opinion in Neurology*, **2016**, 29, 782-788	7.1	19
103	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). *Clinical Cancer Research*, **2016**, 22, 4797-4806	12.9	77
102	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncology, The*, **2016**, 17, 1521-1532	21.7	294
101	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. *Genome Biology*, **2015**, 16, 16	18.3	65
100	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. *Neuro-Oncology*, **2015**, 17, 708-17	1	148
99	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro-Oncology*, **2015**, 17, 1064-75	1	356
98	Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison. *Scientific Reports*, **2015**, 5, 15375	4.9	15
97	CSIG-05THE UBIQUITIN SPECIFIC PEPTIDASE 15 (USP15) SUPPRESSES PROLIFERATION OF HUMAN GLIOBLASTOMA CELL LINES VIA STABILIZATION OF HECTD1 E3 LIGASE. *Neuro-Oncology*, **2015**, 17, v67.1-v67	1	78
96	Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. *Journal of Neuroscience*, **2015**, 35, 15097-112	6.6	41
95	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2535-43	27.4	696
94	Reply to M.C. Chamberlain. *Journal of Clinical Oncology*, **2014**, 32, 1634-5	2.2	2
93	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1100-8	21.7	629
92	MGMT testing--the challenges for biomarker-based glioma treatment. *Nature Reviews Neurology*, **2014**, 10, 372-85	15	316
91	GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA. *Neuro-Oncology*, **2014**, 16, iii8-iii8	1	78
90	EG-05COMBINATION OF GENE COPY GAIN AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX-SIGNATURE IN GLIOBLASTOMA. *Neuro-Oncology*, **2014**, 16, v75-v76	1	78
89	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. *Journal of Clinical Oncology*, **2014**, 32, 2003-2003	2.2	10

88	Molecular neuro-oncology in clinical practice: a new horizon. *Lancet Oncology, The*, **2013**, 14, e370-9	21.7	149
87	The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. *Neuro-Oncology*, **2013**, 15, 269-78	1	67
86	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. *Journal of Clinical Oncology*, **2013**, 31, 4085-91	2.2	623
85	Epigenetics and Brain Cancer **2013**, 21-40		
84	Brain cancer in 2012: Molecular characterization leads the way. *Nature Reviews Clinical Oncology*, **2013**, 10, 69-70	19.4	11
83	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. *Journal of Clinical Oncology*, **2013**, 31, LBA2003-LBA2003	2.2	24
82	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. *Neuro-Oncology*, **2012**, 14, 1503-10	1	45
81	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncology, The*, **2012**, 13, 916-26	21.7	840
80	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. *European Journal of Cancer*, **2012**, 48, 1176-84	7.5	137
79	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. *Acta Neuropathologica*, **2012**, 124, 547-60	14.3	213
78	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. *European Journal of Cancer, Supplement*, **2012**, 10, 20-26	1.6	
77	Treatment options in elderly patients with glioblastoma □AuthorsRreply. *Lancet Oncology, The*, **2012**, 13, e461-e462	21.7	
76	A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. *PLoS ONE*, **2012**, 7, e41522	3.7	70
75	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). *Cancer*, **2012**, 118, 5601-7	6.4	95
74	Clinical implications of molecular neuropathology and biomarkers for malignant glioma. *Current Neurology and Neuroscience Reports*, **2012**, 12, 302-7	6.6	20
73	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. *Acta Neuropathologica*, **2012**, 123, 841-52	14.3	68
72	Individualized targeted therapy for glioblastoma: fact or fiction?. *Cancer Journal (Sudbury, Mass.)*, **2012**, 18, 40-4	2.2	57
71	DNA fingerprinting of glioma cell lines and considerations on similarity measurements. *Neuro-Oncology*, **2012**, 14, 701-11	1	38

70	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. *Neuro-Oncology*, **2012**, 14 Suppl 4, iv100-8	1	120
69	Epidermal growth factor receptor: a re-emerging target in glioblastoma. *Current Opinion in Neurology*, **2012**, 25, 774-9	7.1	66
68	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. *Journal of Clinical Investigation*, **2012**, 122, 253-66	15.9	108
67	Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma. *Journal of Neuro-Oncology*, **2011**, 103, 59-69	4.8	12
66	Current concepts and management of glioblastoma. *Annals of Neurology*, **2011**, 70, 9-21	9.4	319
65	The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. *Neuro-Oncology*, **2011**, 13, 736-47	1	76
64	Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. *Clinical Cancer Research*, **2011**, 17, 255-66	12.9	67
63	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. *Molecular Cancer Therapeutics*, **2011**, 10, 1102-12	6.1	137
62	Marker-independent identification of glioma-initiating cells. *Nature Methods*, **2010**, 7, 224-8	21.6	66
61	Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. *PLoS ONE*, **2010**, 5, e11084	3.7	55
60	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *Journal of Clinical Oncology*, **2010**, 28, 2712-8	2.2	338
59	Reply to M.C. Chamberlain. *Journal of Clinical Oncology*, **2010**, 28, e696-e697	2.2	
58	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. *Future Oncology*, **2010**, 6, 1407-14	3.6	20
57	Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 729-36	3.1	66
56	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. *Nature Reviews Neurology*, **2010**, 6, 39-51	15	538
55	Molecular diagnostics of gliomas: the clinical perspective. *Acta Neuropathologica*, **2010**, 120, 585-92	14.3	96
54	MGMT promoter methylation in malignant gliomas. *Targeted Oncology*, **2010**, 5, 161-5	5	52
53	Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes. *Cancer Informatics*, **2009**, 7, 91-104	2.4	

52	Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. *PLoS ONE*, **2009**, 4, e5947	3.7	81
51	MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. *Journal of Clinical Oncology*, **2009**, 27, 5881-6	2.2	203
50	Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. *Cancer Research*, **2009**, 69, 458-65	10.1	102
49	Epigenetic deregulation of DNA repair and its potential for therapy. *Clinical Cancer Research*, **2009**, 15, 5026-31	12.9	49
48	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. *BMC Cancer*, **2009**, 9, 308	4.8	61
47	Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. *International Journal of Cancer*, **2009**, 125, 2624-30	7.5	68
46	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncology, The*, **2009**, 10, 459-66	21.7	5111
45	Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. *Brain Pathology*, **2008**, 18, 520-32	6	157
44	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *Lancet Oncology, The*, **2008**, 9, 29-38	21.7	407
43	Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. *Journal of Molecular Diagnostics*, **2008**, 10, 332-7	5.1	145
42	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *Journal of Clinical Oncology*, **2008**, 26, 4189-99	2.2	625
41	Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. *Cancer Research*, **2008**, 68, 6942-52	10.1	36
40	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. *Clinical Cancer Research*, **2008**, 14, 957-60	12.9	110
39	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. *Journal of Clinical Oncology*, **2008**, 26, 3015-24	2.2	541
38	Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. *International Journal of Cancer*, **2008**, 123, 1215-8	7.5	18
37	Chemoradiotherapy in malignant glioma: standard of care and future directions. *Journal of Clinical Oncology*, **2007**, 25, 4127-36	2.2	385
36	MGMT methylation status: the advent of stratified therapy in glioblastoma?. *Disease Markers*, **2007**, 23, 97-104	3.2	39
35	Neuro-oncology: oligodendroglioma and molecular markers. *Lancet Neurology, The*, **2007**, 6, 10-2	24.1	5

34	Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. *Cancer Research*, **2007**, 67, 6163-73	10.1	49
33	Correlative studies in neuro-oncology trials: should they influence treatment?. *Current Oncology Reports*, **2006**, 8, 54-7	6.3	5
32	Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Cancer*, **2006**, 107, 162-70	6.4	47
31	New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. *Neurosurgical Focus*, **2006**, 20, E6	4.2	57
30	Changing paradigms--an update on the multidisciplinary management of malignant glioma. *Oncologist*, **2006**, 11, 165-80	5.7	316
29	Recent developments in the use of chemotherapy in brain tumours. *European Journal of Cancer*, **2006**, 42, 582-8	7.5	95
28	MGMT gene silencing and benefit from temozolomide in glioblastoma. *New England Journal of Medicine*, **2005**, 352, 997-1003	59.2	5267
27	Optimal role of temozolomide in the treatment of malignant gliomas. *Current Neurology and Neuroscience Reports*, **2005**, 5, 198-206	6.6	142
26	Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice. *Toxicologic Pathology*, **2005**, 33, 307-12	2.1	10
25	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clinical Cancer Research*, **2004**, 10, 1871-4	12.9	856
24	Growth promoting signaling by tenascin-C [corrected]. *Cancer Research*, **2004**, 64, 7377-85	10.1	75
23	INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma. *Oncogene*, **2004**, 23, 6854-63	9.2	9
22	Prognostic factors for low-grade gliomas. *Seminars in Oncology*, **2003**, 30, 23-8	5.5	38
21	Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. *Cancer Research*, **2003**, 63, 6613-25	10.1	168
20	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. *Oncogene*, **2002**, 21, 4212-9	9.2	137
19	p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. *Brain Pathology*, **2001**, 11, 296-305	6	22
18	Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. *Oncogene*, **2001**, 20, 1103-9	9.2	58
17	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. *Oncogene*, **2000**, 19, 3816-22	9.2	120

16	Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. *Oncogene*, **2000**, 19, 5329-37	9.2	12
15	No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. *Brain Pathology*, **1999**, 9, 627-37	6	15
14	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome. *International Journal of Cancer*, **1999**, 82, 17-22	7.5	5
13	The mouse ERG before and after light damage is independent of p53. *Documenta Ophthalmologica*, **1998**, 96, 311-20	2.2	5
12	Determination of p53 Mutations, EGFR Overexpression, and Loss of p16 Expression in Pediatric Glioblastomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 782-789	3.1	69
11	Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. *International Journal of Cancer*, **1997**, 73, 57-63	7.5	44
10	Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. *Brain Pathology*, **1995**, 5, 15-23	6	32
9	Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 651-6	3.1	112
8	Hepatic and pulmonary carcinogenicity of methylene chloride in mice: a search for mechanisms. *Toxicology*, **1995**, 102, 73-81	4.4	14
7	Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. *Cancer Research*, **1994**, 54, 6257-64	10.1	62
6	Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. *Carcinogenesis*, **1993**, 14, 803-10	4.6	78
5	Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator. *Carcinogenesis*, **1993**, 14, 145-9	4.6	27
4	Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. *Molecular Carcinogenesis*, **1993**, 8, 177-85	5	59
3	Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. *Science*, **1992**, 258, 1148-52	33.3	456
2	No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet. *Mutation Research - Reviews in Genetic Toxicology*, **1990**, 238, 325-9		32
1	Detection by 32P-postlabeling of thymidine glycol in gamma-irradiated DNA. *Carcinogenesis*, **1989**, 10, 43-7	4.6	41